Vorinostat (rINN) also known as suberanilohydroxamic acid is a member of a larger class of compounds that inhibit histone deacetylases (HDAC).
Drug information on Vorinostat for patients and consumers.
Vorinostat is a new drug used in the management of cutaneous T cell lymphoma when the disease persists, gets worse or comes back during or after treatment ...
Vorinostat (Zolinza) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatment of cutaneous T-cell lymphoma.
Jul 3, 2013 ... On October 6, 2006, the U.S. Food and Drug Administration granted approval to vorinostat (Zolinza™, Merck & Co., Inc.), a histone deacetylase ...
Oct 10, 2006 ... This page contains brief information about vorinostat and a collection of links to more information about the use of this drug, research results, ...
Results of animal studies indicate that vorinostat crosses the placenta and is found in fetal plasma at levels up to 50% of maternal concentrations. Doses.
Vorinostat is a member of the hydroxamic acid subclass of histone deacetylase ( HDAC) inhibitors. Its primary biochemical mechanism is to correct an aberrant ...
Jun 13, 2005 ... Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar ...
Vorinostat also known as SAHA, Zolinza, MK-0683 is an HDAC inhibitor. Vorinostat CAS No 149647-78-9 with purity >99% & solubility DMSO is available.